亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

作者
Adam D. Cohen,Sandra P. Susanibar-Adaniya,Alfred L. Garfall,Dan T. Vogl,Shivani Kapur,Adam Justin Waxman,Danielle Zubka,Wei‐Ting Hwang,Cynthia G. Diaczynsky,Julia Han Noll,Matthew Ho,Luca Paruzzo,Bing Yi,Rong Xu,Elina Thai,Vanessa E. Gonzalez,Peter Michener,Marco Ruella,Joseph A. Fraietta,Edward Allen Stadtmauer
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 699-699 被引量:9
标识
DOI:10.1182/blood-2025-699
摘要

Abstract Background: BCMA-targeted CAR T cells have unprecedented activity in relapsed/refractory multiple myeloma (RRMM), but the majority of patients (pts) relapse. Mechanisms of resistance include lack of persistence or poor function of CAR T cells, as well as BCMA-low or -negative residual tumor cells. FcRH5 is a MM antigen with expression independent of BCMA. Cevostamab (cevo) is an FcRH5-targeted, T cell-engaging bispecific antibody with demonstrated activity in RRMM, including in patients with prior BCMA-directed therapies (Richter et al, ASH 2024, #1021). We hypothesized that fixed-duration cevo following BCMA-targeted CAR T cells would be feasible, tolerable and improve sustained minimal residual disease (MRD)-negative complete response (CR) rates, potentially leading to more durable responses. Methods: This is an ongoing single-institution, investigator-initiated study (NCT05801939), with funding from Genentech/Roche. RRMM pts who received standard of care CAR T cells (ide-cel or cilta-cel) 8-10 weeks prior to enrollment, with stable disease or better, receive cevo at a step-up dose of 3.6 mg intravenously (IV) on Cycle 1 Day 1 (C1D1), followed by full target dose starting on C1D8, then every 3 weeks for total of 8 cycles. If pts are in MRD-negative CR after 8 cycles (Adaptive Clonoseq assay, at 10-5 sensitivity), they stop therapy and are observed. If not, they get another 8 cycles of cevo, and then are observed. Primary endpoint is frequency of MRD-negative CR at 12 months post-CAR T cell therapy. All pts receive IVIG. Results: Twenty-seven pts (20M and 7F; median age 64 (33-80); 21 White, 6 Black) have enrolled. Twenty (74%) had high risk cytogenetics (t(4;14), t(14;16), -17p, -1p, or +1q), with 11 (41%) having ≥2 high risk features; 5 (19%) had extramedullary disease. Median number of prior lines was 4 (2-10), with 74% triple-class refractory, 11% prior BCMA therapy, and 11% prior talquetamab. Twenty-five (93%) received cilta-cel and 2 (7%) ide-cel. Reponses at enrollment (post-CAR T cells) were 63% CR/sCR, 15% VGPR, 18% PR, 4% SD; 25 of 27 pts were evaluable for MRD, with 100% MRD-negative at 10-5. During a safety run-in, 3 pts started cevo 8-10 weeks post-CAR T cells, at a target dose of 160 mg, and during C1 all had grade (G) 1 or 2 allergic-type symptoms (rash, arthralgias, cough and/or bronchospasm) which resolved with anti-histamines and topical or systemic steroids. For this reason, the study was modified to start cevo 10-12 weeks post-CAR T cells and change target dose to 132 mg. As of 6/27/25 data cut-off, no dose-limiting toxicities (DLT) have occurred. CRS occurred in 4 (15%) pts (3 G1, 1 G2) and infusion reactions in 19% (all G1/2); no ICANS or HLH was seen. Median number of cycles is 8, and 6 (22%) pts have had dose reductions from 132 to 90mg. Common treatment-emergent adverse events (TEAE's), regardless of attribution, include lymphopenia (74%, G3/4 67%), neutropenia (74%, G3/4 44%), cough (59%, G3/4 0%), rash 44% (G3/4 0%), thrombocytopenia 41% (G3/4 22%), upper respiratory infection 37% (G3/4 0%), nasal congestion 33% (G3/4 0%), and AST increase 33% (G3/4 7%). Infections were seen in 52% (G3/4 in 15%). Notable immune-related AE's include colitis G1, neuropathy with ataxia G3, ITP G4 (n=2, 1 with prior history), autoimmune hepatitis G1) – all resolved. So far, 22 pts are response-evaluable after 8 cycles, with 81% in stringent CR, 9% in VGPR, 5% in SD; 21/22 (95%) were MRD-negative at 10-5, and 20/22 (91%) at 10-6 (1 pt had PD after C4, counted as MRD+). Only 3 pts to date have required the 2nd 8 cycles of cevo. Fourteen pts are evaluable at 1 year post-CAR T cells, with 93% in MRD-negative (at 10-5) sCR, 79% at 10-6. With median follow-up of 12 months (range 3-25) post-CAR T cells, estimated 12-month PFS and OS are both 95%. Preliminary correlative analyses demonstrate detectable CAR+ T cells (by both qPCR and flow) at enrollment in 2 of 5 pts tested to date; both had modest re-expansion of CAR T cells during C1 of cevo, with persistence out to 1 year.Conclusions: To date, cevostamab consolidation starting 10-12 weeks post-CAR T cell infusion at 3.6mg single step-up and 132mg q3wk target dose appears feasible and well-tolerated in heavily-pretreated RRMM, with low rates of non-hematologic G3/4 TEAE's, including infections. Preliminary efficacy appears promising, with over 90% showing sustained MRD-negative CR at 1 year. Analyses and follow-up are ongoing.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
从容美女发布了新的文献求助10
6秒前
星辰大海的应助被纯情的阁采纳,获得10
6秒前
16秒前
大个的应助被交大·勒布朗采纳,获得30
30秒前
45秒前
成就马里奥完成签到,获得积分10
45秒前
47秒前
50秒前
纯情的阁发布了新的文献求助10
53秒前
1分钟前
深情的从丹完成签到,获得积分10
1分钟前
1分钟前
阿丕啊呸完成签到,获得积分10
1分钟前
1分钟前
1分钟前
null的应助被伊比利亚的微风采纳,获得10
1分钟前
认真的笑卉完成签到,获得积分10
1分钟前
1分钟前
aba发布了新的文献求助10
1分钟前
hamburger完成签到,获得积分10
1分钟前
null的应助被等待若魔采纳,获得10
1分钟前
陶醉成协完成签到,获得积分10
1分钟前
haralee完成签到 ,获得积分10
1分钟前
1分钟前
乐正元正完成签到,获得积分10
1分钟前
时尚的蜜蜂完成签到,获得积分10
2分钟前
2分钟前
369ninja发布了新的文献求助10
2分钟前
2分钟前
2分钟前
Logan1001发布了新的文献求助10
2分钟前
2分钟前
2分钟前
bkagyin的应助被Logan1001采纳,获得10
2分钟前
hyman发布了新的文献求助10
2分钟前
2分钟前
2分钟前
生动琦完成签到,获得积分10
2分钟前
彩色的可冥完成签到,获得积分10
2分钟前
Logan1001完成签到,获得积分20
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158789
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748389
什么是DOI,文献DOI怎么找? 3427080
关于科研通互助平台的介绍 2551987
邀请新用户注册赠送积分活动 2471354